NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company that entered the public markets in 2021 through its business combination with Big Rock Partners Acquisition Corp, a blank-check vehicle sponsored by Big Rock Partners. The company is focused on developing treatments for central nervous system disorders and critical care conditions, including programs targeting bipolar depression and suicidality. NRX filed an 8-K with the Securities and Exchange Commission on September 12, 2025, under accession number 0001437749-25-028949. As a post-de-SPAC issuer, NRXP continues to trade on Nasdaq. For complete filing history, corporate event timelines, and SPAC transaction analytics on NRX Pharmaceuticals and thousands of other deals, sign up for full data access at SpacDesk.